Butyphthalide Therapy Of Cerebrovascular Diseases With Meta Analysis

Objective:Use a Meta systematic method to evaluate butypathalide in the treatment of cerebral infarction,cerebral ischemic stroke and Alzheimer's disease,provide novel methods of the treatment of the three diseases,and provide evidence in clinic.Method:Retrieve references in the MEDLINE-Pubmed,WANGFANG,,VIP,CNKI, CBMdisc 5 databases and related journals for the randomized controlled trials(RCTs) on the comparison of effectiveness and safety of butypathalide in the treatment of cerebral infarction,cerebral ischemic stroke and Alzheimer's disease.Two reviewers independently screened the eligible studies,with confirmation of cross-check. Different opinions were consulted by the third party.Meta-analysis was done by Revman 4.2.10.Data were pooled using fixed effect model if without heterogeneity (P＞0.05),otherwise,sensitivity analysis,subgroup analysis or randomized effect model was adopted.Results:Twenty-five original studies met inclusion criteria,its included 2192 participants.Quality classification for 2 class-A,B-class 9 and C-class 14. Meta-analysis showed that:(1) The treatment of cerebral infarction:①Butypathalide treatment group and control group(normal method) to improve symptoms of cerebral infarction related to the difference was stastiscally significant[P≤0.01,OR=3.53,95%CI(2.55,4.89)].②Butypathalide treatment group and control group(normal method) have a significant difference on the NIHSS value[P＜0.01,WMD=-3.03,95%CI(-3.48,-2.58)].③Butypathalide treatment group and control group(normal method) have a significant difference on the Barthel value[P＜0.01,WMD=6.39,95%CI(2.65,10.12)].④Butypathalide treatment group and control group(aspirin tablets) to improve symptoms of cerebral infarction related to the difference was stastiscally significant[OR=3.55,95%CI(1.37,9.20),P≤0.05].⑤Butypathalide treatment group and control group(aspirin tablets) have a significant difference on the NIHSS value[WMD=-1.57,95%CI(-1.91,-1.23),P＜0.01].⑥Butypathalide treatment group and control group(other method) to improve symptoms of cerebral infarction related to the difference was stastiscally significant[OR=3.97,95%CI(1.83,8.64),P≤0.01].⑦Butypathalide treatment group and control group(other method) have a significant difference on the NIHSS value[WMD=-1.41,95%CI(-1.75,-1.07),P＜0.01].(2) The treatment of cerebral ischemic stroke:Butypathalide treatment group and control group have a significant difference on the TIA relapse rate[OR=0.34, 95%CI(0.12,0.96),P≤0.5].(3) The treatment of Alzheimer's disease: Butypathalide treatment group and control group have a significant difference on the MMSE value[WMD=3.59,95%CI(2.80,4.38),P＜0.01].Conclusion:On currently available results show that butypathalide have some advantages on the treatment of cerebral infarction,cerebral ischemic stroke and Alzheimer's disease.All included in the study of literature exists experimental design and implementation issues,such as scientific and reliable to draw conclusions needed to conduct high quality,large sample and multi-centers randomized controlled trial.